慢性肾脏病(CKD)已成为威胁全人类健康的一类重大疾病.在CKD患者中,矿物质和骨代谢紊乱十分常见.以往临床诊疗规范采用美国肾脏基金会于2004年制定的肾脏疾病患者生存治疗(KDOQI)指南.2009年,改善全球肾脏病预后组织(KDIGO)颁布了适用于全球的慢性肾脏病-矿物质和骨异常(CKD-MBD)的诊断、评估、预防和治疗的临床实践指南.文章从CKD-MBD的生化指标异常、骨组织学改变和血管钙化3个方面,对两个指南中存在的不同点逐一进行解读.%Disturbances in mineral and bone metabolism are common in patients with chronic kidney disease (CKD). We used to follow Kidney Disease Outcomes Quality Initiative( KDOQI) established by National Kidney Foundation(NKF) in 2004. In 2009,Kidney Disease:Improving Global Outcomes(KDIGO) published the mineral and bone disorder of chronic kidney disease guidelines. We will review the differences between KDOQI and KDI-GO.
展开▼
